Literature DB >> 20528445

Impact of dose frequency on compliance and health outcomes: a literature review (1966-2006).

Lizheng Shi1, Meredith Hodges, Nicole Yurgin, Kristina S Boye.   

Abstract

In order for treatments to be effective, patients must be compliant with their medication regimens. Currently, patient compliance is seen as one of the most challenging issues in treating patients with chronic diseases. Studies in which dose frequency has been changed have been reviewed across several different diseases to examine the impact of a change in dose frequency on compliance and health outcomes, as well as efficacy and tolerability. In general, reducing dose frequency may improve medication compliance and effectiveness, and reduce adverse events, while possibly reducing healthcare costs. Suggestions for future research have been presented, including a need to measure compliance with injectable formulations and a standardized definition of compliance.

Entities:  

Year:  2007        PMID： 20528445     DOI： 10.1586/14737167.7.2.187

Source DB:  PubMed          Journal:  Expert Rev Pharmacoecon Outcomes Res        ISSN： 1473-7167            Impact factor:   2.217


  10 in total

1.  Treatment adherence to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and systemic lupus erythematosus.

Authors:  Sofia de Achaval; Maria E Suarez-Almazor
Journal:  Int J Clin Rheumtol       Date:  2010-06-01

Review 2.  Erythropoietin or darbepoetin for patients with cancer.

Authors:  Thomy Tonia; Annette Mettler; Nadège Robert; Guido Schwarzer; Jerome Seidenfeld; Olaf Weingart; Chris Hyde; Andreas Engert; Julia Bohlius
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

3.  Utilities and disutilities for attributes of injectable treatments for type 2 diabetes.

Authors:  Kristina S Boye; Louis S Matza; Kimberly N Walter; Kate Van Brunt; Andrew C Palsgrove; Aodan Tynan
Journal:  Eur J Health Econ       Date:  2010-03-12

4.  Letter to the Editor From Malozowski: "Weekly Lonapegsomatropin in Treatment-naïve Children with Growth Hormone Deficiency: the Phase 3 heiGHt Trial".

Authors:  Saul Malozowski
Journal:  J Clin Endocrinol Metab       Date:  2022-04-19       Impact factor: 5.958

Review 5.  Erythropoietin or Darbepoetin for patients with cancer--meta-analysis based on individual patient data.

Authors:  Julia Bohlius; Kurt Schmidlin; Corinne Brillant; Guido Schwarzer; Sven Trelle; Jerome Seidenfeld; Marcel Zwahlen; Mike J Clarke; Olaf Weingart; Sabine Kluge; Margaret Piper; Maryann Napoli; Dirk Rades; David Steensma; Benjamin Djulbegovic; Martin F Fey; Isabelle Ray-Coquard; Volker Moebus; Gillian Thomas; Michael Untch; Martin Schumacher; Matthias Egger; Andreas Engert
Journal:  Cochrane Database Syst Rev       Date:  2009-07-08

6.  Electronic monitoring of oral therapies in ethnically diverse and economically disadvantaged patients with rheumatoid arthritis: consequences of low adherence.

Authors:  Christian A Waimann; Maria F Marengo; Sofia de Achaval; Vanessa L Cox; Araceli Garcia-Gonzalez; John D Reveille; Marsha N Richardson; Maria E Suarez-Almazor
Journal:  Arthritis Rheum       Date:  2013-06

Review 7.  The Effect of Space Travel on Bone Metabolism: Considerations on Today's Major Challenges and Advances in Pharmacology.

Authors:  Shirley Genah; Monica Monici; Lucia Morbidelli
Journal:  Int J Mol Sci       Date:  2021-04-27       Impact factor: 5.923

8.  Impact of Medication Regimen Simplification on Medication Administration Times and Health Outcomes in Residential Aged Care: 12 Month Follow Up of the SIMPLER Randomized Controlled Trial.

Authors:  Janet K Sluggett; Ria E Hopkins; Esa Yh Chen; Jenni Ilomäki; Megan Corlis; Jan Van Emden; Michelle Hogan; Tessa Caporale; Choon Ean Ooi; Sarah N Hilmer; J Simon Bell
Journal:  J Clin Med       Date:  2020-04-08       Impact factor: 4.241

9.  Impact of reducing dosing frequency on adherence to oral therapies: a literature review and meta-analysis.

Authors:  Kunal Srivastava; Anamika Arora; Aditi Kataria; Joseph C Cappelleri; Alesia Sadosky; Andrew M Peterson
Journal:  Patient Prefer Adherence       Date:  2013-05-20       Impact factor: 2.711

10.  Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial.

Authors:  Paul S Thornton; Aristides K Maniatis; Elena Aghajanova; Elena Chertok; Elpis Vlachopapadopoulou; Zhengning Lin; Wenjie Song; Eva Dam Christoffersen; Vibeke Miller Breinholt; Tatiana Kovalenko; Elene Giorgadze; Maria Korpal-Szczyrska; Paul L Hofman; David B Karpf; Aimee D Shu; Michael Beckert
Journal:  J Clin Endocrinol Metab       Date:  2021-10-21       Impact factor: 5.958
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.